Certara, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $80.39M normalized FCF base (TTM); 9% annual FCF growth yrs 1-5; 5% yrs 6-10; 9% discount rate; 3% terminal growth; $117.08M net debt ($301.95M debt vs. $184.14M cash); 152.54M shares outstanding.

Reasoning: Certara is a steady, high-margin biosimulation software and services provider (Simcyp platform) with recurring regulatory-submission-driven demand; consistent double-digit-to-high-single-digit growth and a market-average discount rate reflect its moderate but durable competitive position in a niche drug-development software market.